1 |
Pouillon L, Travis S, Bossuyt P, Danese S, Peyrin-Biroulet L. Head-to-head trials in inflammatory bowel disease: past, present and future. Nat Rev Gastroenterol Hepatol 2020;17:365-76. [PMID: 32303700 DOI: 10.1038/s41575-020-0293-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
2 |
Ma C, Guizzetti L, Jairath V. Improving Clinical Trial Efficiency in Gastroenterology. Gastroenterology 2019;157:892-3. [DOI: 10.1053/j.gastro.2019.02.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
|
3 |
Xie L, Zhu Y, Liang Z, Zhao Y, Zhou S, Chen J, Zhang H, Ding S, Wang L, Shao F. Pharmacokinetics, Tolerability, Safety, and Immunogenicity of LY01008 and Bevacizumab (Avastin®) in Healthy Chinese Subjects. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35112328 DOI: 10.1007/s13318-021-00752-7] [Reference Citation Analysis]
|
4 |
Su S, Shen J, Zhu L, Qiu Y, He JS, Tan JY, Iacucci M, Ng SC, Ghosh S, Mao R, Liang J. Involvement of digestive system in COVID-19: manifestations, pathology, management and challenges. Therap Adv Gastroenterol 2020;13:1756284820934626. [PMID: 32595762 DOI: 10.1177/1756284820934626] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 11.5] [Reference Citation Analysis]
|